APCCC 2024 VL

Managing Frail Patients with Metastatic Hormone-Sensitive Prostate Cancer - Maria De Santis

Details
Maria De Santis discusses managing frail patients with metastatic hormone-sensitive prostate cancer. Dr. De Santis explains the importance of defining frailty, which involves five key factors: unintended weight loss, weakness, low physical activity, difficulty lifting objects, and mobility issues. She highlights the necessity of evaluating frailty using tools like the G8 screening and emphasizes t...

Redefining Low-Volume Metastatic Prostate Cancer in the Era of PSMA PET Imaging - Oliver Sartor

Details
Oliver Sartor discusses his approach to treating low-volume metastatic prostate. Dr. Sartor emphasizes the importance of molecular imaging, particularly PSMA PET, to define low-volume and oligometastatic disease accurately. He advocates for a "total therapy" approach, combining androgen deprivation, novel hormones, and targeted radiation, including SBRT for metastatic sites and pelvic radiation. D...

Optimal Imaging Standards for Metastatic Castration-Sensitive Prostate Cancer - Michael Morris

Details
Michael Morris discusses optimal imaging standards for metastatic hormone-sensitive prostate cancer. He explains that conventional imaging methods like PSA tracking are insufficient for monitoring disease progression in the era of advanced androgen receptor signaling inhibitors (ARSIs). Dr. Morris emphasizes the need for regular imaging, recommending scans every six to twelve months to detect radi...

The Use of PARP Inhibitors in mCRPC with BRCA1/2 Alterations - Joaquin Mateo

Details
Alicia Morgans speaks with Joaquin Mateo about his presentation on PARP inhibitors. Dr. Mateo discusses the role of PARP inhibitors in treating metastatic castration-resistant prostate cancer (mCRPC) with BRCA1 or BRCA2 mutations, noting the poor prognosis associated with these mutations but highlighting the effectiveness of PARP inhibitors like olaparib and rucaparib. He explains the differences...

Bone Health in Advanced Prostate Cancer: Findings from the STAMPEDE Trial and Hospital Episode Statistics - Noel Clarke

Details
Alicia Morgans engages with Noel Clarke on the critical issue of bone health in prostate cancer patients, particularly those undergoing androgen deprivation therapy (ADT). Professor Clarke shares findings from the STAMPEDE trial and other studies that highlight the high fracture rates in these patients. He criticizes the reliability of the FRAX scoring system, which was originally developed for a...

APCCC 2024: Bridging Clinical Gaps in Prostate Cancer Care - Silke Gillessen

Details
Silke Gillessen discusses thr upcoming APCCC 2024 and delves into how the conference will tackle crucial topics from GU ASCO 2024, highlighting the dynamic field of prostate cancer treatment. Dr. Gillessen mentions the incorporation of new data, such as the findings from Dr. Maha Hussain's BRCAAWAY presentation, into the APCCC's already prepared questions. These discussions aim to address clinical...

Highlighting APCCC 2024: An International Prostate Cancer Meeting - Silke Gillessen & Aurelius Omlin

Details
Alicia Morgans hosts a discussion with Professors Silke Gillessen and Aurelius Omlin about the upcoming APCCC 2024, emphasizing its significance for the prostate cancer community. The congress invites all interested in prostate cancer management, offering a blend of clinical and translational research insights. The conversation also touches on the congress's inclusivity, encouraging participation...